Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series.
Gori N, Ippoliti E, Ferrucci SM, Balato A, Ortoncelli M, Maurelli M, Galluzzo M, Munera Campos M, Seremet T, Di Nardo L, Antonelli F, Coscarella G, Conrad C, Carrascosa JM, Bianchi L, Argenziano G, Ribero S, Girolomoni G, Marzano AV, Chiricozzi A, Peris K; MEDaCoTRA Study Group. Gori N, et al. Among authors: ferrucci sm. J Eur Acad Dermatol Venereol. 2024 Feb 29. doi: 10.1111/jdv.19929. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38421043 No abstract available.
Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV, Genovese G, Casazza G, Fierro MT, Dapavo P, Crimi N, Ferrucci S, Pepe P, Liberati S, Pigatto PD, Offidani A, Martina E, Girolomoni G, Rovaris M, Foti C, Stingeni L, Cristaudo A, Canonica GW, Nettis E, Asero R. Marzano AV, et al. J Eur Acad Dermatol Venereol. 2019 May;33(5):918-924. doi: 10.1111/jdv.15350. Epub 2018 Dec 7. J Eur Acad Dermatol Venereol. 2019. PMID: 30451325 Free article.
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Sirna R, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavò SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Savi E, Stingeni L, Romano A, Argenziano G; Dupilumab Italian National Access Program (Dup-INAP group). Fargnoli MC, et al. J Dermatolog Treat. 2021 Aug;32(5):507-513. doi: 10.1080/09546634.2019.1682503. Epub 2019 Oct 28. J Dermatolog Treat. 2021. PMID: 31647347 Free article.
128 results